Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | CASR | P41180 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cgp-12177 SCHEMBL12329633 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| Cgp-12177 SCHEMBL4538049 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL10594616 | 0.89 | ADRB3 (0.80) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL11230530 | 0.86 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL11331685 | 0.86 | ADRB2 (0.75) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL11462740 | 0.85 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL11242745 | 0.84 | ADRB2 (0.73) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL11248041 | 0.83 | ADRB2 (0.73) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL16187027 | 0.83 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CYP1A2MEN1 | |
| SCHEMBL16189744 | 0.83 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| EP-4536239-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2025-04-16 | — | — | EP | claimed |
| WO-2025050038-A2 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2025-03-06 | — | — | WO | claimed |
| CN-119562815-A | GPCR inhibitors and uses thereof | GPCR治疗公司 | 2025-03-04 | — | — | CN | claimed |
| US-20240301022-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | UNIV ASTON (GB) | 2024-09-12 | — | — | US | claimed |
| WO-2023239937-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2023-12-14 | — | — | WO | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-20220273751-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2022-09-01 | — | — | US | claimed |
| EP-3969007-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2022-03-23 | — | — | EP | claimed |
| CN-114051416-A | GPCR heteromer inhibitors and uses thereof | GPCR治疗公司 | 2022-02-15 | — | — | CN | claimed |
| CN-114028370-A | Composition with effects of preventing and treating obesity and related diseases and application thereof | 中山大学 | 2022-02-11 | — | — | CN | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2004089288-A2 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-0003298-B1 | 4-HYDROXY-2-BENZIMIDAZOLIN-THION DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-03-25 | — | — | EP | disclosed |
| EP-0000784-A1 | 4-Hydroxy-2-benzimidazolinone derivatives, process for their preparation and their use in medicaments | Roche Diagnostics GmbH (DE) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRD, GABRB3 | ADRB2 19/4885ADRB1 60/4885ADRB3 71/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ADRB2 177/4885ADRB1 161/4885ADRB3 131/4885 |
| US-20260021061-A1 | ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS | ATXN2, HCRTR2, CDR2 | ADRB2 135/4885ADRB1 487/4885ADRB3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.